---
title: "Allogene Therapeutics 3Q 2026: Revenue $0, EPS ($0.15) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304625075.md"
description: "Allogene Therapeutics reported $0 revenue and a net loss of $50.37M for Q3 2026, widening from the prior year due to increased R&D spending on product advancement and hiring. Cash reserves stood at $388.9M, supporting operations into Q1 2029. Key pipeline updates include enrollment in Cema-cel's ALPHA3 trial, ongoing RESOLUTION study for ALLO-329, and completed enrollment for ALLO-316's Phase 1b expansion."
datetime: "2026-11-06T11:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304625075.md)
  - [en](https://longbridge.com/en/news/304625075.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304625075.md)
generator: "portal-rs"
---

# Allogene Therapeutics 3Q 2026: Revenue $0, EPS ($0.15) — 10-Q Summary

Allogene Therapeutics reported no collaboration revenue in the third quarter, unchanged from a year earlier, while its net loss widened as research and development spending rose with product-candidate advancement, manufacturing reactivation and increased hiring. Higher interest and other income partly offset the expense increase.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$0

$0

—

Net income²

($50.37M)

($41.4M)

(21.7%)

Diluted EPS³

($0.15)

($0.19)

21.1%

*¹ Reported as “Collaboration revenue - related party”. ² Reported as “Net loss”. ³ Reported as “Net loss per share, basic and diluted”.*

**Business Highlights**

-   **Cema-cel**: ALPHA3 was enrolling at more than 80 sites across the U.S., Canada, South Korea and Australia; the company anticipates an update in mid-2027.
-   **ALLO-329**: RESOLUTION enrollment continued, with dose escalation and lymphodepletion optimization ongoing; an optional fludarabine-and-cyclophosphamide arm was activated.
-   **ALLO-316**: The company completed enrollment of 20 treated patients in the TRAVERSE Phase 1b expansion cohort and is exploring strategic opportunities, including potential partnerships.
-   **Cash runway**: Cash, cash equivalents and investments totaled $388.9M at September 30, 2026; the company expects funding into the first quarter of 2029.

Original SEC Filing: Allogene Therapeutics, Inc. \[ ALLO \] - 10-Q - Nov. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)

## Related News & Research

- [Allogene's ALLO-329 improves skin scores in 8 of 10 scleroderma patients in Phase 1 trial](https://longbridge.com/en/news/304856012.md)
- [ALLO: ALLO-329 showed early SSc activity across LD approaches, including no lymphodepletion](https://longbridge.com/en/news/304856871.md)
- [Allogene Therapeutics (ALLO) Expected to Release Earnings on Thursday](https://longbridge.com/en/news/303544335.md)
- [Allogene Highlights CAR T Clinical Progress in Kidney Cancer at SITC Meeting](https://longbridge.com/en/news/304117819.md)
- [Allogene Therapeutics Plans to Attend Three Investor Conferences](https://longbridge.com/en/news/303083684.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**